References
- Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827–33.
- Jonsson D, Husberg M. Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care 2000;16:1193–200.
- Boers M. Rheumatoid arthritis. Treatment of early disease. Rheum Dis Clin North Am 2001;27:405–14.
- van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Heurkens AH, Haanen HC, Bijlsma JW. Direct cost of rheumatoid arthritis during the first six years: a cost- of-illness study. Br J Rheumatol 1998;37:837–47.
- Cooper NJ, Mugford M, Scott DG, Barrett EM, Symmons DP. Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK. J Rheumatol 2000;27:2115–22.
- Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis [Western Con-sortium of Practicing Rheumatologists]. J Rheumatol 2000; 27:1156–63.
- Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528–34.
- Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347–56.
- Toivanen A, Toivanen P. Reactive arthritis. CUff Opin Rheumatol 2000;12:300–5.
- Soderlin MK, Borjesson O, Kautiainen H, Skogh T, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002;61:911–5.
- Soderlin MK, Kautiainen H, Puolakkainen M, Hedman K, Soderlund-Venermo M, Skogh T, et al. Infections preceding early arthritis: a prospective population-based study in Southern Sweden. J Rheumatol 2003;30:459–64.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
- Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55–78.
- Fister RD, Weymouth LA, McLaughlin JC, Ryan RW, Tilton RC. Comparative evaluation of three products for the detection of Borrelia burgdorferi antibody in human serum. J Clin Microbiol 1989;27:2834–7.
- Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308–15.
- Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996;44:47–51.
- Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28–33.
- Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single- drug or combination-disease-modifying antirheumatic drug therapy in early rheu-matoid arthritis. Arthritis Rheum 2002;46:894–8.
- Puolakka K, Kautiainen H, Mottonen T, Korpela M, Hannonen P, Julkunen H, et al. Initial aggressive drug treatment with DMARDs prevents work disability in early rheumatoid arthritis. Arthritis Rheum 2002;46:375.
- Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310–9.